Artwork

Content provided by Tom Aarts. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Tom Aarts or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

NBT # 25 Sarah Kennedy and Dr. Ed Walker: Ozempic & Natural Alternatives that Work

45:37
 
Share
 

Manage episode 410685336 series 3566825
Content provided by Tom Aarts. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Tom Aarts or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

On this latest episode of Nutrition Business Today, host Tom Aarts and his guests pick apart this surge of weight loss supplements, that followed the recent 'Ozempic craze'.
Coming all the way from New Zealand, six-time CEO Sarah Kennedy and scientist lecturer at the University of Aukland, Dr. Ed Walker cut through the noise on natural products in this category and what claims have the science to back them up
Ozempic, just one of the pharmaceutical semaglutide injectables developed for diabetes, has stormed the media with its effectiveness when it comes to weight loss and management. But is there cause for concern? Are some users unable to withstand the side effects, or perhaps they are not comfortable with injections? Regardless, consumers are looking for natural alternatives and Calocurb's patented delivery of the main ingredient, Amerasate, is the only natural GLP-1 agonist on the market. With a $20 million research investment from the NZ government, Calocurb has the science to solidify these claims. Join us as we discuss what it takes from a business and science perspective to enter this volatile category.
Find Calocurb at https://www.calocurb.com/
For interested practitioners, visit https://wholesale.calocurb.com/

  continue reading

27 episodes

Artwork
iconShare
 
Manage episode 410685336 series 3566825
Content provided by Tom Aarts. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Tom Aarts or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

On this latest episode of Nutrition Business Today, host Tom Aarts and his guests pick apart this surge of weight loss supplements, that followed the recent 'Ozempic craze'.
Coming all the way from New Zealand, six-time CEO Sarah Kennedy and scientist lecturer at the University of Aukland, Dr. Ed Walker cut through the noise on natural products in this category and what claims have the science to back them up
Ozempic, just one of the pharmaceutical semaglutide injectables developed for diabetes, has stormed the media with its effectiveness when it comes to weight loss and management. But is there cause for concern? Are some users unable to withstand the side effects, or perhaps they are not comfortable with injections? Regardless, consumers are looking for natural alternatives and Calocurb's patented delivery of the main ingredient, Amerasate, is the only natural GLP-1 agonist on the market. With a $20 million research investment from the NZ government, Calocurb has the science to solidify these claims. Join us as we discuss what it takes from a business and science perspective to enter this volatile category.
Find Calocurb at https://www.calocurb.com/
For interested practitioners, visit https://wholesale.calocurb.com/

  continue reading

27 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide